Angis Capital Downgrades Galectin Therapeutics, Inc.

Loading...
Loading...
In a note released Friday morning, Aegis Capital analyst, Raghuram Selvaraju downgraded shares of Galectin Therapeutics, Inc.
GALT
from Buy to Hold. The downgrade comes amid results concerns as to whether or not the company will be able to demonstrate clinical effectiveness of its lead drug candidate GR-MD-02. The concerns arose when the second cohort of its Phase 1b trial did not show the same indications of potential anti-fibrotic efficacy as the previous cohort. Amid the Aegis downgrade shares of have dropped over seven percent in Friday's market session to ~$5.70.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorNewsDowngradesPrice TargetAnalyst RatingsMoversAegis Capital
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...